|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
New York Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing New YorkLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
PLx Pharma Inc.
| | | Phone: | (212) 269-2834 | Fax: | (212) 269-2580 | Year Established: | 2010 | Ticker: | DPRX | Exchange: | NASDAQ | Main Contact: | Natasha Giordano, President & CEO | | Other Contacts: | Michael Valentino, Executive Chairman
| |
| Company Description | PLx Parma, previously Dipexium Pharmaceuticals, is focused on completion of manufacturing scale-up and label finalization for the previously conditionally approved AspertecTM 325 mg aspirin dosage form thereby satisfying the open conditional items, and filing of a supplemental new drug application (sNDA) for Aspertec 81 mg maintenance dose form. Aspertec is being developed to provide high-risk cardiovascular and neurology patients with more reliable and predictable antiplatelet efficacy as compared to enteric coated aspirin while also reducing the adverse gastric events common in an acute setting. | |
|
|
|
|
|